Our findings support the existence of a cross-talk between estrogen/ER-signalling and growth factors in ER+ HER2 non-amplified tumour implicating a greater potential of increased growth-factor dependent signalling in tumours compared to normal breast tissue. This evidence concerns the gene ESR1 and neoplasm.